A seperate thread to hold facts relating to Argenica's lead drug candidate ARG-007 as given by the company. A poster (@Bendustan) is seeking to flood this stock board with misleading and inaccurate views based on a cursory but limited understanding of the drug class with ulterior motives (primarily to undermine the stock price or influence shareholders with fear uncertainty and doubt).
Following the publishing of this thread you will most likely see an attempt by @Bendustan to repeatedly have his posts dominate the thread whereby his posts are the final say. Most people will spot this in a short period of time not least of all because of the incessant repeated falsehoods with spurious links to irrelevant research papers, but for newcomers this serves as a reminder to be aware of this person's methods and manipulation.
Do your own research and check suppositions against your own findings.
Relating to the drug ARG-007 (from Argenica's press releases):
- ARG-007 has a plurifunctional mechanism of action, affecting neuronal excitotoxicity, calcium influx and mitochondrial dysfunction, and reducing the activation of damaging proteolytic enzymes which greatly enhances its neuroprotective potential and translational clinical effectiveness
- It is confirmed ARG-007 does not impact the clot dissolving activity of tPA, indicating ARG-007 can be used with the standard of care tPA therapy.
- ARG-007 does not permanently downregulate receptors responsible for calcium influx, suggesting the drug mechanism of action will not cause neurotoxicity.
- The data further demonstrates that ARG-007 has a unique mechanism of action and pharmacological benefits compared to competitor drug
- ARG-007 has no impact on genetic material up to the determined maximum tolerated dose of 17.5 mg/kg.
- Significant neuroprotection from a single dose of ARG-007 lasted out to 12 hours, post 12 hours the neuroprotective effect dropped away. Neuroprotection was again restored when an additional dose was given post 12 hours. This indicates that after 12 hours the glutamate receptors return to normal function enabling neuronal signal transmission. This is an important safety consideration, because drugs that permanently block glutamate receptors have severe neurotoxic side effects. This study indicates that ARG-007 does not permanently block glutamate receptors, and therefore ARG-007 presents as an ideal drug candidate for acute neurological indications including ischaemic stroke where receptors are only required to be down regulated for a limited period of time to safeguard against stroke induced excitotoxicity prior to the blood flow being restored.
- Given ARG-007 is a D-isomer peptide it is resistant to proteolytic degradation and therefore is not readily degraded in the body, this was confirmed in Argenica’s Phase 1 clinical trial showing a 12–15-hour half-life.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)